Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 412

1.

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.

Soverini S, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A, Iurlo A, Luciano L, Pregno P, Rosti G, Saglio G, Stagno F, Tiribelli M, Vigneri P, Barosi G, Breccia M.

J Hematol Oncol. 2019 Dec 5;12(1):131. doi: 10.1186/s13045-019-0815-5. Review.

2.

Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.

Sommer K, Cottone F, Aaronson NK, Fayers P, Fazi P, Rosti G, Angelucci E, Gaidano G, Venditti A, Voso MT, Baccarani M, Vignetti M, Efficace F.

Qual Life Res. 2019 Nov 28. doi: 10.1007/s11136-019-02369-5. [Epub ahead of print]

PMID:
31782016
3.

Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies.

Efficace F, Cottone F, Sommer K, Kieffer J, Aaronson N, Fayers P, Groenvold M, Caocci G, Lo Coco F, Gaidano G, Niscola P, Baccarani M, Rosti G, Venditti A, Angelucci E, Fazi P, Vignetti M, Giesinger J.

Value Health. 2019 Nov;22(11):1303-1310. doi: 10.1016/j.jval.2019.06.004. Epub 2019 Aug 7.

PMID:
31708068
4.

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.

Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, Patriarca A, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G.

Leukemia. 2019 Sep 2. doi: 10.1038/s41375-019-0563-0. [Epub ahead of print]

PMID:
31477798
5.

Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.

Baccarani M, Rosti G, Soverini S.

Leukemia. 2019 Oct;33(10):2358-2364. doi: 10.1038/s41375-019-0562-1. Epub 2019 Aug 27. Review.

PMID:
31455852
6.

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.

Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, Annunziata M, Stagno F, Tiribelli M, Binotto G, Bonifacio M, Fava C, Iurlo A, Bucelli C, Mansueto G, Gozzini A, Falzetti F, Montefusco E, Crisà E, Gugliotta G, Russo S, Cedrone M, RussoRossi A, Pregno P, Isidori A, Mauro E, Atelda R, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Galimberti S, Orlandi E, Calistri E, Bocchia M, Cavazzini F, Rege Cambrin G, Orofino N, Luciano L, Sgherza N, Rosti G, Latagliata R, Capodanno I.

Ann Hematol. 2019 Oct;98(10):2329-2338. doi: 10.1007/s00277-019-03767-y. Epub 2019 Aug 7.

PMID:
31392461
7.

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.

Mancini M, De Santis S, Monaldi C, Bavaro L, Martelli M, Castagnetti F, Gugliotta G, Rosti G, Santucci MA, Martinelli G, Cavo M, Soverini S.

J Exp Clin Cancer Res. 2019 May 23;38(1):216. doi: 10.1186/s13046-019-1197-9.

8.

Primary mediastinal germ cell tumors.

Rosti G, Secondino S, Necchi A, Fornarini G, Pedrazzoli P.

Semin Oncol. 2019 Apr;46(2):107-111. doi: 10.1053/j.seminoncol.2019.04.001. Epub 2019 Apr 24. Review.

PMID:
31076171
9.

Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica.

Banna GL, Nicolai N, Palmieri G, Ottaviano M, Balzarini L, Barone D, Basso U, Bavila A, Bertoni F, Calliada F, Cai T, Carrafiello G, Condello C, Da Pozzo L, Di Nardo D, Fornarini G, Prayer Galetti T, Garolla A, Giannatempo P, Guerra L, La Spina S, Malatino L, Marchiano' A, Monti M, Morbiato FF, Morelli F, Nole' F, Palazzi S, Procopio G, Rosti G, Sacco C, Salvetti A, Salvioni R, Sava T, Secondino S, Serpentini S, Spreafico C, Tavolini IM, Valcamonico F, Verri E, Zucali P, De Giorgi U.

Crit Rev Oncol Hematol. 2019 May;137:154-164. doi: 10.1016/j.critrevonc.2019.03.006. Epub 2019 Mar 20. Review.

PMID:
31014511
10.

Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management.

Casadei C, Schepisi G, Menna C, Chovanec M, Gurioli G, Gallà V, Altavilla A, Marcellini M, Bellia SR, Lolli C, Mego M, Rosti G, De Giorgi U.

Future Oncol. 2019 Apr;15(12):1347-1352. doi: 10.2217/fon-2018-0850. Epub 2019 Mar 18. Review.

PMID:
30880465
11.

Psychosocial Issues in Long-Term Survivors of Testicular Cancer.

Schepisi G, De Padova S, De Lisi D, Casadei C, Meggiolaro E, Ruffilli F, Rosti G, Lolli C, Ravaglia G, Conteduca V, Farolfi A, Grassi L, De Giorgi U.

Front Endocrinol (Lausanne). 2019 Feb 25;10:113. doi: 10.3389/fendo.2019.00113. eCollection 2019. Review.

12.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

13.

The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.

Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, Pfirrmann M; International BCR-ABL Study Group.

Leukemia. 2019 May;33(5):1173-1183. doi: 10.1038/s41375-018-0341-4. Epub 2019 Jan 23.

14.

Reply to: Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO).

Caccialanza R, Rosti G, Carminati O, Pedrazzoli P.

Support Care Cancer. 2019 May;27(5):1589-1590. doi: 10.1007/s00520-018-4584-4. Epub 2018 Dec 4. No abstract available.

PMID:
30515572
15.

Intragenic duplication of KCNQ5 gene results in aberrant splicing leading to a premature termination codon in a patient with intellectual disability.

Rosti G, Tassano E, Bossi S, Divizia MT, Ronchetto P, Servetti M, Lerone M, Pisciotta L, Mancardi MM, Veneselli E, Puliti A.

Eur J Med Genet. 2019 Sep;62(9):103555. doi: 10.1016/j.ejmg.2018.10.007. Epub 2018 Oct 22.

PMID:
30359776
16.

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261. doi: 10.1093/annonc/mdy159. No abstract available.

PMID:
30285223
17.

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D.

Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018.

18.

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G.

Expert Opin Drug Saf. 2018 Jun;17(6):623-628. doi: 10.1080/14740338.2018.1480719. Epub 2018 May 30. Review.

PMID:
29845876
19.

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Ricciardi MR, Salvestrini V, Licchetta R, Mirabilii S, Forcato M, Gugliotta G, Salati S, Castagnetti F, Rosti G, Breccia M, Alimena G, Manfredini R, Bicciato S, Lemoli RM, Tafuri A.

Oncotarget. 2018 Apr 24;9(31):21758-21769. doi: 10.18632/oncotarget.24938. eCollection 2018 Apr 24.

20.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Efficace F, Castagnetti F, Martino B, Breccia M, D'Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G.

Cancer. 2018 May 15;124(10):2228-2237. doi: 10.1002/cncr.31323. Epub 2018 Mar 2.

Supplemental Content

Loading ...
Support Center